​

Medpace (MEDP) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MEDP Stock Forecast

Medpace (MEDP) stock forecast, based on 19 Wall Street analysts, predicts a 12-month average price target of $498.86, with a high of $582.00 and a low of $400.00. This represents a 21.78% increase from the last price of $409.65.

$300 $360 $420 $480 $540 $600 High: $582 Avg: $498.86 Low: $400 Last Closed Price: $409.65

MEDP Stock Rating

Medpace stock's rating consensus is Hold, based on 19 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (31.58%), 12 Hold (63.16%), 1 Sell (5.26%), and 0 Strong Sell (0.00%).

Hold
Total 19 0 1 12 6 Strong Sell Sell Hold Buy Strong Buy

MEDP Price Target Upside V Benchmarks

TypeNameUpside
StockMedpace21.78%
SectorHealthcare Stocks 15.45%
IndustryDiagnostics & Research Stocks32.98%

Price Target Trends

1M3M12M
# Anlaysts41017
Avg Price Target$452.75$501.60$530.82
Last Closing Price$409.65$409.65$409.65
Upside/Downside10.52%22.45%29.58%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 261381-13
Mar, 26-371213
Feb, 26-183113
Jan, 26-183113
Dec, 25-183113
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 24, 2026BMO Capital$400.00$402.81-0.70%-2.36%
Apr 24, 2026Ryan HalstedRBC Capital$484.00$393.4223.02%18.15%
Apr 24, 2026Eric ColdwellRobert W. Baird$477.00$393.4221.24%16.44%
Apr 24, 2026Luke SergottBarclays$450.00$393.4214.38%9.85%
Mar 06, 2026Luke SergottBarclays$500.00$468.366.76%22.06%
Feb 13, 2026David WindleyJefferies$560.00$416.0434.60%36.70%
Feb 11, 2026Truist Financial$539.00$431.1725.01%31.58%
Feb 11, 2026Mizuho Securities$582.00$446.0530.48%42.07%
Feb 11, 2026BMO Capital$460.00$446.053.13%12.29%
Feb 10, 2026Robert W. Baird$564.00$455.6423.78%37.68%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 24, 2026RBC CapitalOutperformOutperformhold
Mar 03, 2026RBC CapitalSector PerformOutperforminitialise
Feb 18, 2026Cowen & Co.SellHoldupgrade
Feb 13, 2026JefferiesHoldBuyupgrade
Feb 11, 2026BMO CapitalMarket PerformMarket Performhold
Dec 15, 2025BarclaysUnderweightUnderweighthold
Oct 24, 2025Cowen & Co.SellSellhold
Oct 02, 2025BarclaysCautiousUnderweightdowngrade
Sep 09, 2025JefferiesHoldHoldhold
Jul 23, 2025Cowen & Co.BuySelldowngrade

Financial Forecast

EPS Forecast

$0 $4 $8 $12 $16 $20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$5.06$7.57$9.20$13.06$15.64---
Avg Forecast$4.78$6.97$8.64$11.94$12.52$14.32$16.54$18.08
High Forecast$4.94$7.34$8.97$12.02$12.68$15.97$17.31$18.76
Low Forecast$4.56$6.85$8.63$11.84$12.28$13.57$15.84$17.75
Surprise %5.86%8.61%6.48%9.38%24.92%---

Revenue Forecast

$1B $2B $2B $3B $3B $4B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.14B$1.46B$1.89B$2.11B$2.53B---
Avg Forecast$1.14B$1.45B$1.89B$2.11B$2.21B$2.46B$2.76B$3.14B
High Forecast$1.17B$1.51B$1.94B$2.17B$2.22B$2.48B$2.76B$3.23B
Low Forecast$1.10B$1.43B$1.86B$2.08B$2.20B$2.43B$2.75B$3.09B
Surprise %-0.04%0.56%-0.02%0.12%14.68%---

Net Income Forecast

$100M $200M $300M $400M $500M $600M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$181.85M$245.37M$282.81M$404.39M$451.12M---
Avg Forecast$159.74M$178.50M$282.62M$379.75M$403.41M$458.58M$527.76M$575.69M
High Forecast$191.68M$214.20M$339.14M$382.61M$403.71M$508.54M$551.09M$597.27M
Low Forecast$127.79M$142.80M$226.10M$376.88M$390.88M$432.23M$504.43M$565.27M
Surprise %13.84%37.46%0.07%6.49%11.83%---

MEDP Forecast FAQ

Is Medpace stock a buy?

Medpace stock has a consensus rating of Hold, based on 19 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 12 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Medpace is a neutral investment for most analysts.

What is Medpace's price target?

Medpace's price target, set by 19 Wall Street analysts, averages $498.86 over the next 12 months. The price target range spans from $400 at the low end to $582 at the high end, suggesting a potential 21.78% change from the previous closing price of $409.65.

How does Medpace stock forecast compare to its benchmarks?

Medpace's stock forecast shows a 21.78% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the diagnostics & research stocks industry (32.98%).

What is the breakdown of analyst ratings for Medpace over the past three months?

  • April 2026: 7.69% Strong Buy, 23.08% Buy, 61.54% Hold, 7.69% Sell, 0% Strong Sell.
  • March 2026: 0% Strong Buy, 23.08% Buy, 53.85% Hold, 7.69% Sell, 15.38% Strong Sell.
  • February 2026: 0% Strong Buy, 7.69% Buy, 61.54% Hold, 23.08% Sell, 7.69% Strong Sell.

What is Medpace’s EPS forecast?

Medpace's average annual EPS forecast for its fiscal year ending in December 2026 is $14.32, marking a -8.44% decrease from the reported $15.64 in 2025. Estimates for the following years are $16.54 in 2027, and $18.08 in 2028.

What is Medpace’s revenue forecast?

Medpace's average annual revenue forecast for its fiscal year ending in December 2026 is $2.46B, reflecting a -2.85% decrease from the reported $2.53B in 2025. The forecast for 2027 is $2.76B, and $3.14B for 2028.

What is Medpace’s net income forecast?

Medpace's net income forecast for the fiscal year ending in December 2026 stands at $458.58M, representing an 1.65% increase from the reported $451.12M in 2025. Projections indicate $527.76M in 2027, and $575.69M in 2028.